Neurocrine Biosciences Inc (NBIX) Insider Trading
- $39,032,821.44
- $330,070,616.07
- May 15, 2024
- Kevin Charles Gorman
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
April 19, 2023 | Director | 903 | $105.00 | Sell | $94,815.00 | |
Feb. 23, 2023 | Major Shareholder | 4,395,588 | $8.88 | Buy | $39,032,821.44 | |
Feb. 8, 2023 | CEO | 2,274 | $104.30 | Sell | $237,178.20 | |
Feb. 8, 2023 | Insider | 980 | $104.12 | Sell | $102,037.60 | |
Feb. 7, 2023 | CFO | 26,328 | $102.40 | Sell | $2,695,987.20 | |
Feb. 6, 2023 | CEO | 3,040 | $105.68 | Sell | $321,267.20 | |
Feb. 6, 2023 | Insider | 1,280 | $105.63 | Sell | $135,206.40 | |
Jan. 31, 2023 | CEO | 2,707 | $110.08 | Sell | $297,986.56 | |
Jan. 31, 2023 | Insider | 1,457 | $109.99 | Sell | $160,255.43 | |
Jan. 31, 2023 | CFO | 1,283 | $109.98 | Sell | $141,104.34 | |
Jan. 6, 2023 | Insider | 400 | $125.00 | Sell | $50,000.00 | |
Jan. 3, 2023 | Director | 30,000 | $118.86 | Sell | $3,565,800.00 | |
Nov. 30, 2022 | Insider | 50,000 | $125.90 | Sell | $6,295,000.00 | |
Nov. 10, 2022 | Insider | 100 | $125.36 | Sell | $12,536.00 | |
Nov. 8, 2022 | Insider | 24,593 | $125.33 | Sell | $3,082,240.69 | |
Nov. 3, 2022 | Insider | 4,518 | $125.02 | Sell | $564,840.36 | |
Nov. 1, 2022 | Insider | 10,000 | $120.09 | Sell | $1,200,900.00 | |
Oct. 31, 2022 | Director | 15,000 | $114.76 | Sell | $1,721,400.00 | |
Oct. 27, 2022 | Insider | 4,923 | $115.04 | Sell | $566,341.92 | |
Oct. 17, 2022 | Insider | 4,960 | $110.82 | Sell | $549,667.20 | |
Oct. 4, 2022 | Director | 5,000 | $110.54 | Sell | $552,700.00 | |
Oct. 3, 2022 | Insider | 1,437 | $106.59 | Sell | $153,169.83 | |
Aug. 12, 2022 | Insider | 21,533 | $105.95 | Sell | $2,281,421.35 | |
June 27, 2022 | Insider | 754 | $100.00 | Sell | $75,400.00 | |
May 9, 2022 | Director | 15,000 | $76.30 | Sell | $1,144,500.00 | |
April 25, 2022 | Director | 15,000 | $92.76 | Sell | $1,391,400.00 | |
April 1, 2022 | Director | 10,728 | $94.93 | Sell | $1,018,409.04 | |
March 22, 2022 | Insider | 8,455 | $95.05 | Sell | $803,647.75 | |
March 18, 2022 | Insider | 300 | $95.00 | Sell | $28,500.00 | |
Feb. 7, 2022 | CEO | 8,710 | $80.82 | Sell | $703,942.20 | |
Feb. 7, 2022 | Insider | 240 | $81.07 | Sell | $19,456.80 | |
Feb. 7, 2022 | CFO | 3,310 | $80.79 | Sell | $267,414.90 | |
Jan. 24, 2022 | Director | 15,000 | $74.43 | Sell | $1,116,450.00 | |
Jan. 10, 2022 | Insider | 2,632 | $74.50 | Sell | $196,084.00 | |
Jan. 5, 2022 | Insider | 28,266 | $85.50 | Sell | $2,416,743.00 | |
Dec. 1, 2021 | CFO | 1,645 | $82.59 | Sell | $135,860.55 | |
Oct. 7, 2021 | Director | 5,000 | $105.06 | Sell | $525,300.00 | |
Oct. 7, 2021 | Insider | 8,000 | $104.81 | Sell | $838,480.00 | |
Oct. 4, 2021 | Insider | 987 | $101.73 | Sell | $100,407.51 | |
Aug. 16, 2021 | Insider | 5,628 | $89.62 | Sell | $504,381.36 | |
July 27, 2021 | Insider | 16,709 | $93.80 | Sell | $1,567,304.20 | |
June 10, 2021 | Director | 10,000 | $100.27 | Sell | $1,002,700.00 | |
Feb. 10, 2021 | Insider | 1,700 | $119.96 | Sell | $203,932.00 | |
Feb. 8, 2021 | CFO | 2,910 | $116.82 | Sell | $339,946.20 | |
Feb. 8, 2021 | CEO | 10,466 | $116.75 | Sell | $1,221,905.50 | |
Feb. 8, 2021 | Insider | 2,363 | $116.78 | Sell | $275,951.14 | |
Feb. 5, 2021 | Insider | 865 | $114.15 | Sell | $98,739.75 | |
Feb. 5, 2021 | CEO | 2,422 | $114.16 | Sell | $276,495.52 | |
Jan. 26, 2021 | Insider | 1,100 | $119.97 | Sell | $131,967.00 | |
Jan. 25, 2021 | Director | 1,600 | $120.03 | Sell | $192,048.00 |
Insiders are both buying and selling Neurocrine Biosciences Inc stock.
The insider traders at Neurocrine Biosciences Inc are: Kevin Charles Gorman, Darin Lippoldt, Haig P Bozigian, Dimitri E Grigoriadis, Gary A Lyons, Christopher Flint Obrien, Matt Abernethy, Eiry Roberts, Eric Benevich, Timothy P Coughlin, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, William H Rastetter, Ingrid Delaet, David W Boyer, Julie Cooke, W Thomas Mitchell, Timothy Coughlin, Stephen A Sherwin, Corinne H Nevinny, Jude Onyia, Haig Bozigian, Dimitri Grigoriadis, Haig P. Bozigian, Gary A. Lyons, George J. Morrow, Dimitri E. Grigoriadis, Leslie V. Norwalk, and Neurocrine Biosciences Inc
The most active insider trader at Neurocrine Biosciences Inc is Kevin Charles Gorman with 41 trades.
Kevin Charles Gorman has sold the most Neurocrine Biosciences Inc stock with a total value of $98,873,670.68.
Neurocrine Biosciences Inc has bought the most Neurocrine Biosciences Inc stock with a total value of $78,065,642.88.
The most recent insider trade for Neurocrine Biosciences Inc was on May 15, 2024.
The single biggest insider buy for Neurocrine Biosciences Inc was from Neurocrine Biosciences Inc with a total value of $39,032,821.44 on Feb. 23, 2023.
The single biggest insider sell for Neurocrine Biosciences Inc was from Kevin Charles Gorman with a total value of $33,975,315.00 on Jan. 8, 2021.